Statements (19)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Agilent_Technologies
|
| gptkbp:acquisitionYear |
2021
|
| gptkbp:focusesOn |
cancer diagnostics
liquid biopsy |
| gptkbp:foundedIn |
2012
|
| gptkbp:headquartersLocation |
gptkb:Kirkland,_Washington,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Resolution Bioscience
|
| gptkbp:industry |
gptkb:biotechnology
healthcare |
| gptkbp:offersProduct |
gptkb:Resolution_ctDx_Lung
|
| gptkbp:offersService |
liquid biopsy testing for non-small cell lung cancer
|
| gptkbp:parentCompany |
gptkb:Agilent_Technologies
|
| gptkbp:platform |
cfDNA NGS (circulating free DNA next-generation sequencing)
|
| gptkbp:regulates |
gptkb:FDA_Emergency_Use_Authorization_(EUA)_for_COVID-19_test
|
| gptkbp:specializesIn |
next-generation sequencing
|
| gptkbp:website |
https://www.resolutionbio.com/
|
| gptkbp:bfsParent |
gptkb:Agilent_Technologies
|
| gptkbp:bfsLayer |
6
|